Shares of Cytori Therapeutics Inc. (NASDAQ:CYTX) fell to a one-year low of $1.46 Wednesday morning after the company disclosed late Tuesday that it placed a clinical hold on enrollment in the phase II ATHENA and ATHENA II trials of its adipose-derived regenerative cells (ADRCs) in heart failure patients.